Search Results

Hundreds to Climb Iconic Bank of America Tower to End Blood Cancer

FDA Approves Targeted Treatment for Rare, Aggressive form of Blood Cancer

LLS Announces Expansion of Precision Medicine Approach to Fight Blood Cancer

FDA Approval of AML Therapy is a Significant Advance for Blood Cancer Patients

Jordin Sparks Joins Burlington Stores And LLS To Fight Blood Cancers

Optimizing Clinical Outcomes in Blood Cancers through Groundbreaking Translational Research

Hematopoietic Cell Transplantation as Treatment for Blood Cancers: The Team Approach - For Nurses

Blood Cancer Patients Need Support Now More Than Ever

NCI Genetic Epidemiology Branch- Familial Blood and Lymph Node Cancers

To study families with multiple cases of lymphoproliferative disorders.

  • The National Cancer Institute (NCI) of the National Institutes of Health (NIH) is studying the causes of familial blood and lymph node cancers. The primary focus is on: Chronic lymphocytic leukemia (CLL), Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Waldenstrom’s macroglobulinemia (WM), and Multiple myeloma (MM).
  • The clinical evaluation includes a medical history and physical examination and may also entail disease-related laboratory or imaging studies. In certain cases, patients may be invited to visit the NIH Warren G. Magnuson Clinical Center in Bethesda, Maryland, for evaluation. Otherwise, study components can often be completed in or near the patient's home community.
     

Families with 2 or more living individuals in the family with a history of the same lymphoproliferative disorder

800-518-8474 https://dceg.cancer.gov/research/clinical-studies/blood-lymph-cancers

Shred For Red: An Unstoppable Community Hits the Slopes to End Blood Cancer

Love, Strength, Support: Sibling care in pediatric blood cancer journeys

Coping with Childhood Blood Cancer: The Power of Play and Creative Therapies for Families

Closer to a Cure Inspires & Educates About Treatment Advances of Blood Cancers

FDA Approval of New Precision Medicine Therapy for Deadly Blood Cancer

Burlington Stores and LLS Bring Smiles to Those Touched by Blood Cancers

Could Humor Help Your Family Cope with a Blood Cancer Diagnosis?

Supporting Lifesaving Medicaid Expansion for Patients

On November 6, citizens in Idaho, Nebraska, and Utah approved ballot measures to expand Medicaid in their states. These landmark votes will close the coverage gap for more than 360,000 people in these states who earn too much to qualify for traditional Medicaid but not enough to get help with the cost of buying individual coverage.

scientist

Highlights from ASCO 2021

Dexamethasone

Dexamethasone, hydrocortisone, methylprednisolone and prednisone are FDA approved corticosteroids that are used to treat many medical problems, including some kinds of cancer.

Aaron Bird Bear

Practicing Self-Advocacy During My PTCL Journey

Paying Tribute to a Legacy: Executive Challenge Winners Recognized

This year’s Light The Night Executive Challenge ended with a bittersweet roundup of results. The winner, Stacey Weathers, former long-time executive director of The Leukemia & Lymphoma Society’s (LLS) New Jersey chapter, was tragically killed this past October when a tree fell on her car during a storm. Even though she isn’t here to celebrate with her LLS colleagues and family, her worthy achievement will be recognized as her legacy lives on.  

A Powerful Force

MLB All-Star Player Designs Caps to Benefit LLS

The Leukemia & Lymphoma Society (LLS) hit a homerun when the Washington Nationals outfielder, Bryce Harper announced LLS will be a beneficiary of his limited edition, custom-designed baseball caps.   Known for extraordinary talents in the outfield, Bryce’s talent as a hat designer is now getting recognition: He helped design the New Era caps which went on sale Wednesday, August 24.

Pegfilgrastim

Pegfilgrastim is FDA approved to

Bendamustine hydrochloride

Bendamustine hydrochloride is FDA approved to treat people who have:

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. 

Reflections from the #ASH19 Meeting

As the 61st Annual ASH (American Society of Hematology) Meeting and Exhibition winds down here in Orlando, here are some thoughts on where things stand in the world of blood cancers.